Gentamicin Sulfate

（金牌讲师刘光辉老师教学⬆️） 地塞米松能抑制白细胞、吞噬细胞在炎症部位的聚集，减轻组织对炎症的反应，在临床目前常用来抗炎、抗过敏，并且是危重疾病的急救药物。 但国内外多项研究表明，地塞米松与很多药物配伍会产生不良反应，现总结如下，供各位参考。 一、药物相互作用 1、与巴比妥类、苯妥英钠、利福平同时服用，地塞米松代谢促进作用减弱； 2、与利尿剂合用，会使血钾降低； 3、与碳酸酐酶抑制剂、两性霉素 B 合用，会加重低血钾； 4、与蛋白质同化激素合用，易产生痤疮； 5、与麻黄碱合用，会强化地塞米松效果； 6、与阿托品长期合用，会升高患者眼压； 7、可减弱抗凝药的作用，应注意调整剂量； 8、与水杨酸类药物合用，会增加水杨酸类药物的毒性，所以尽量避免，如果必须使用应酌情减量； 9、与维生素 A 作用相拮抗，应避免合用。 二、相关配伍禁忌 （点击可查看大图） -广告- 可的松、泼尼松、地塞米松......，13 种糖皮质激素你了解多少？ 🤔 可的松、泼尼松、地塞米松…有何区别？ ❓长效、中效、短效......等效剂量怎么换算？ 👊🏻 应用糖皮质激素，要警惕哪些不良反应？ ✅ 避免停药反应，具体怎么撤药？ 🔥 免费直播！为了帮助大家更好地掌握糖皮质激素的临床应用，丁香公开课特邀同济大学附属同济医院的刘光辉老师带来「糖皮质激素：临床应用与病例实战」全分享！ 糖皮质激素： 临床应用与病例实战 ⏰ 12 月 26 日（周四）19:00  （扫码报名，免费观看👇） 免费直播，还有「干货分享 + 奖品」👇 一、60 min 干货分享 ✔️超实用分享：搞定糖皮质激素用法和用量计算，盘点常见不良反应，「用药总结+病例实战」手把手教你搞定糖皮质激素！ 同济大学附属同济医院内分泌代谢科刘光辉老师分享宝贵临床经验。 二、福利多多，直播间专属！ 🎁「值班必备：急症处理宝典」、「丁香园咖啡杯」免费抽~现场更有超多惊喜抽奖，助你搞定临床诊疗！ （扫二维码报名，当天我们提醒您👇） （策划：夏夏）（题图：丁香公开课设计） 参考资料： [1]王柳. 葡萄糖酸钙与地塞米松配伍禁忌[J]. 临床军医杂志,2011,39(6):1137. [2]祝金龙,冯锦强. 异丙嗪与地塞米松存在配伍禁忌[J]. 临床军医杂志,2011,39(5):891. [3]吴玲艳,叶雯. 氯化钙溴化钠注射液与地塞米松存在配伍禁忌[J]. 中华医院感染学杂志,2009,19(13):1764. [4]董玉兰,刘丽春,齐海燕. 盐酸溴己新注射液与庆大霉素、地塞米松存在配伍禁忌[J]. 中国实用护理杂志,2012,13(13):93-94. [5]陈洁彬,王芝珊. 谷氨酸诺氟沙星注射液与地塞米松磷酸钠存在配伍禁忌[J]. 中国误诊学杂志,2011,11(7):1742. [6]杨宝珍,蒋维连. 咪达唑仑注射液与地塞米松磷酸注射液存在配伍禁忌[J]. 中华现代护理杂志,2013,19(1):103. [7]马福颖,刘红艳,赵春艳. 甘露醇注射液与注射用地塞米松磷酸钠存在配伍禁忌1例[J]. 黑龙江医药科学,2012,35(6):42. [8]陈嘹. 长春西汀注射液与地塞米松磷酸钠注射液存在配伍禁忌[J]. 中国实用护理杂志,2012,13(13):23.  [9]苏鸽萍. 法莫替丁注射液与地塞米松磷酸钠注射液存在配伍禁忌[J]. 中国实用护理杂志,2009,25(26):60. [10]俞霞. 盐酸托烷司琼注射液与地塞米松磷酸钠注射液存在配伍禁忌[J]. 当代护士（中旬刊）,2015(2):189-189. [11]冀海锋,韩红维. 盐酸昂丹司琼与地塞米松磷酸钠、速尿注射液存在配伍禁忌[J]. 中国误诊学杂志,2009,9(2):483-483. [12]李永翠,毛勇,李莉. 甲磺酸罗哌卡因注射液与地塞米松磷酸钠注射液存在配伍禁忌[J]. 中国实用护理杂志,2012,28(35):89. [13]王巧霞,李桂花,买晓琴,等. 地塞米松磷酸钠注射液与盐酸苯海拉明注射液存在配伍禁忌[J]. 中国实用护理杂志,2013,29(20):37. [14]曾竹. 低分子量肝素钙注射液与地塞米松磷酸钠注射液存在配伍禁忌[J]. 护理实践与研究,2016,13(13):72-72. [15]张楠,李芳. 葡萄糖酸依诺沙星与地塞米松存在配伍禁忌[J]. 中国民康医学,2008,20(6):598-598.

OSAKA, Japan and CAMBRIDGE, MA, USA I December 13, 2024 I Takeda ( TSE:4502/NYSE:TAK ) today announced that the company is working with the European Medicines Agency (EMA) to voluntarily withdraw the marketing authorization of Alofisel® (darvadstrocel), a treatment for complex perianal fistulas in patients with Crohn’s disease, in the European Union (EU). Alofisel is an allogeneic stem cell therapy that is approved in the EU for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy. 1 Alofisel should be used only after conditioning of the fistulas. The initial authorization of Alofisel in the EU was based on results from the Phase 3 ADMIRE-CD placebo-controlled registrational study. 1 Given the small population size (n = 212) and modest benefit observed in the ADMIRE-CD study (a difference of 15.8% between the modified intention-to-treat population versus placebo at 24 weeks), Takeda agreed to provide results from ADMIRE-CD II, a study that was underway, to confirm Alofisel’s efficacy. 1-3 In October 2023, Takeda communicated ADMIRE-CD II , a randomized placebo-controlled study of 568 patients with complex CPF, did not meet its primary endpoint of combined remission at 24 weeks. 3-5 Additional results, which were presented at the European Crohn’s and Colitis Organisation Congress 2024 in February, showed no statistical differences in any of the secondary endpoints. 5 The safety profile for Alofisel was consistent with prior studies as no new, emerging safety signals were identified. 2,4,5 “Guided by our values and the needs of patients living with this difficult-to-treat condition, we engaged the EMA, as well as health care professionals and others in the community, to review the totality of data and the role of our medicine,” said Ramona Sequeira, president, Global Portfolio Division, at Takeda. “Those valuable discussions indicated that despite the conflicting results across our data, the clinical benefit of Alofisel is no longer sufficient to justify its continued use in the EU. We recognize the difficulty of this outcome for patients and will work closely with the Crohn’s Perianal Fistulas (CPF) community during this transition.” In addition to the EU, Takeda is engaging health authorities about this outcome in countries where Alofisel is currently approved, keeping the best interest of patients at the forefront. Takeda is committed to continuing to share data from clinical and observational studies for the benefit of patients and the entire health care community, with the hope that these insights can contribute to scientific advancements in complex CPF. Health care professionals with medical-related questions about Alofisel should contact Takeda Medical Information at medinfoEMEA@takeda.com or medinfoAPAC@takeda.com . Patients should consult their treating health care professional if they have questions. About Alofisel® Alofisel® (darvadstrocel) is a dispersion for injection of expanded human allogeneic mesenchymal adult stem cells extracted from adipose tissue (expanded adipose stem cells – eASC) for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease. Therapeutic Indications Alofisel is indicated for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy. Alofisel should be used only after conditioning of the fistulas. Important Safety Information Contraindications Hypersensitivity to the active substance, bovine serum or to any of the excipients. Special warnings and special precautions for use Alofisel may contain trace amounts of either gentamicin or benzylpenicillin and streptomycin. This should be considered in patients with known hypersensitivity to these classes of antibiotics. Local anaesthesia is not recommended due to the unknown effect of local anaesthetics on the injected cells. The injection of any substance other than sodium chloride 9 mg/mL (0.9%) solution (e.g. hydrogen peroxide, methylene blue, iodine solutions or hypertonic glucose solutions) through the fistula tracts is not allowed before, during, or after the injection of Alofisel as these may compromise the viability of the cells. Alofisel must not be administered using a needle thinner than 22G. Thinner gauge needles can cause cell disruption during injection and may compromise cell viability and, therefore, may affect efficacy of treatment. As Alofisel is a living stem cell therapy it cannot be sterilised, a risk of transmission of infectious agents exists, although the risk is considered to be low and controlled in the manufacturing process. Healthcare professionals administering darvadstrocel must, therefore, monitor patients for signs and symptoms of infections after treatment and treat appropriately, if needed. Alofisel should only be administered by specialist physicians experienced in the diagnosis and treatment of conditions for which darvadstrocel is indicated. Patients treated with Alofisel must not donate blood, organs, tissues and cells for transplantation. The traceability requirements of cell-based therapy medicinal products must apply. Fertility, Pregnancy & Lactation No data is available from the use of darvadstrocel in pregnant women. Darvadstrocel is not recommended during pregnancy and in women of childbearing potential who are not using contraception. As a precautionary measure, darvadstrocel is not recommended for administration during breast-feeding. Undesirable effects Based on clinical trial and post-marketing data, the most commonly reported adverse drug reactions were anal abscess, proctalgia and anal fistula with the most commonly reported serious adverse drug reactions of anal abscess and anal fistula. Procedural pain is associated to conditioning reactions occurring up to seven days after the fistula preparation for treatment administration. For EU audiences, please see the Summary of Product Characteristics (SmPC) for Alofisel®. Please consult with your local regulatory agency for approved labeling in your country. Takeda in Gastroenterology Takeda is committed to meeting the very real needs of those living with gastrointestinal (GI) diseases. We believe that GI and liver diseases are life-disrupting conditions. Beyond a fundamental need for effective treatment options, we understand that improving patients’ lives also depends on their needs being recognized. With more than 35 years of experience in gastroenterology, Takeda has made significant strides in addressing patient needs with treatments for inflammatory bowel disease, eosinophilic esophagitis, acid-related diseases, short bowel syndrome and motility disorders. We are making significant strides toward closing the gap on new areas of unmet need. Together with researchers, patient groups and others, we are working to advance scientific research and clinical medicine in GI. About Takeda Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com . References SOURCE: Takeda Pharmaceutical Co